Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY4R | P50391 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25488117 | 0.98 | SIRT5 (0.40) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL20153097 | 0.94 | SIRT5 (0.41) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL20180535 | 0.93 | SIRT5 (0.41) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL14887361 | 0.93 | SIRT2 (0.42) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL19841587 | 0.93 | SIRT5 (0.41) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL17752434 | 0.92 | SIRT5 (0.42) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL19370636 | 0.92 | SIRT5 (0.42) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL19456879 | 0.92 | SIRT2 (0.49) | SIRT2SIRT1SIRT3 | |
| SCHEMBL16091795 | 0.92 | SIRT5 (0.42) | SIRT5SIRT2SIRT1SIRT3NPY1R | |
| SCHEMBL18556685 | 0.92 | SIRT5 (0.42) | SIRT5SIRT2SIRT1SIRT3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20180134794-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | MET, HGF, HGFAC | SIRT5 4792/4885SIRT2 4878/4885SIRT1 4885/4885 |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | SIRT5 4792/4885SIRT2 4878/4885SIRT1 4885/4885 |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | FGFR2, FGFR3, FGFR1 | SIRT5 4287/4885SIRT2 3330/4885SIRT1 4754/4885 |
| US-20180134794-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | SIRT5 4792/4885SIRT2 4878/4885SIRT1 4885/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | SIRT5 2853/4885SIRT2 4113/4885SIRT1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.